Related Experiment Video
Updated: Aug 15, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
Herpes Zoster vaccination coverage and its determinants in older adults: A Meta-analysis
Hugo Guillermou1, Charlotte De Choudens2, Anke Bourgeois3
1INSERM, CIC 1411, Clinical Investigation Center 1411, CHU Montpellier, Univ Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France; Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, University of Nimes, Nimes, France.
Background:
Herpes zoster is associated with morbidity in older adults and immunocompromised individuals. Despite the availability of effective vaccines, vaccination uptake remains poorly quantified and heterogeneous across countries.
Objectives:
To estimate herpes zoster vaccination coverage among individuals for whom vaccination is recommended based on age in their respective countries, and to identify factors associated with vaccine uptake and temporal trends.
Methods:
Data sources: MEDLINE, CENTRAL, Web of Science, CINAHL, Google Scholar, reference lists, and grey literature sources were searched through June 2025.
Study Eligibility Criteria:
Studies reporting herpes zoster vaccination coverage in age-eligible populations according to national or regional recommendations were included.
Participants:
Older adults eligible for herpes zoster vaccination based on age-based recommendations in their respective countries.
Interventions:
No intervention effects were evaluated. Vaccination status under routine care was assessed. Assessment of risk of bias: Risk of bias was assessed using the Hoy et al. tool for prevalence studies.
Methods:
of data synthesis: Vaccination coverage was pooled using a random-effects meta-analysis of proportions. Meta-regression and subgroup analyses explored determinants of uptake, including population characteristics, vaccine availability, reimbursement policies, and country-level indicators of vaccine confidence.
Results:
Thirty-eight studies from 13 countries were included, covering data collected between 2007 and 2025. Herpes zoster vaccination coverage ranged from 0% to 53%. The pooled vaccination coverage across included countries was 14% (95% CI: 9-20%), with high heterogeneity. Higher uptake was associated with influenza and pneumococcal vaccination coverage, educational level, reimbursement policies, longer time since vaccine introduction, and greater public trust in vaccine effectiveness and scientific institutions. Herpes zoster vaccination coverage increased over time following vaccine implementation.
Conclusions:
Herpes zoster vaccination coverage remains low and highly unequal. Uptake is mainly driven by healthcare system organization and integration within adult immunization programs, highlighting the importance of structured vaccination policies to improve prevention worldwide.
Related Concept Videos
Chickenpox
Pharmacodynamics in Geriatric Patients: Effects of Age
Genital Herpes
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption